Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

Dasatinib and Nilotinib As Upfront Therapy for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in Qatar: A Cost Effectiveness Analysis (CEA)

Ahmad M Adel, MSc, Dina Abushanab, MSc, Anas Hamad, PhD, Mohammad Abdul-Jaber Abdulla, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5850.

https://doi.org/10.1182/blood-2019-121833

Published: 2019

Journal Articles

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Qiujun Shao, Simran Tiwana, Nicholas Despiegel, Franziska Dirnberger

Blood (2019) 134 (Supplement_1): 5814.

https://doi.org/10.1182/blood-2019-126309

Published: 2019

Journal Articles

Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis

Michael Sebag, MD PhD, Julie Stakiw, MD, Thomas J. Stephens, Amie Padhiar, Tony Kim, Jane Shum, Sujith Dhanasiri, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 70.

https://doi.org/10.1182/blood-2019-123636

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis

Ang Li, MD, Josh J Carlson, PhD, Nicole M. Kuderer, Jordan K Schaefer, MD, Shan Li, PharmD, David A. Garcia, MD, Alok A Khorana, MD, Marc Carrier, MD, Gary H. Lyman, MD MPH

Blood (2019) 134 (Supplement_1): 4669.

https://doi.org/10.1182/blood-2019-127917

Published: 2019

Journal Articles

Study of Treatment-Free Remission Evaluation in Real-World Chronic Myeloid Leukemia; Cost-Effectiveness Analysis

Bora Nam, MBA, PhD, Soktae Kim, MBA, PhD, Jae Hoon Lee, MD PhD, Kwai Han Yoo, MD, Jeong-Yeal Ahn, MD, Hawk Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2018-99-116422

Published: 2018

Journal Articles

Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective

Zheng-Yi Zhou, PhD, Kejal Parikh, Xinglei Chai, Ariel Rokito, Chuka Udeze, Jipan Xie, Amit Agarwal

Blood (2018) 132 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2018-99-112942

Published: 2018

Journal Articles

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Gabriel Tremblay, DBA, MSc, BS, Mike Dolph, MSc BHSc, Anuja Roy, PhD, Juliette Neyra, PharmD, Khalid El Ouagari, Anna Forsythe, PharmD, MSc, MBA

Blood (2017) 130 (Supplement 1): 3410.

https://doi.org/10.1182/blood.V130.Suppl_1.3410.3410

Published: 2017

Journal Articles

Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Yanni Hao, PhD, Lamis K. Eldjerou, MD, Hongbo Yang, PhD, Cynthia Qi, MBA, Denise Globe, PhD

Blood (2017) 130 (Supplement 1): 609.

https://doi.org/10.1182/blood.V130.Suppl_1.609.609

Published: 2017

Journal Articles

Resource Utilization Using Micro-Costing Method and Cost Effectiveness Analysis of Treatment of Acute Promyelocytic Leukemia with Generic Arsenic-Trioxide

Aniket Bankar, MD, Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Nisham PN, MD DM, Anu Korula, MD DM, Aby Abraham, MD DM, Alok Srivastava, MD, Sezlian S, Visali Jeyaseelan, PhD, Jasmine Prasad, MD, Biju George, MDDM, Vikram Mathews, MD DM

Blood (2017) 130 (Supplement 1): 3392.

https://doi.org/10.1182/blood.V130.Suppl_1.3392.3392

Published: 2017

Journal Articles

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Gili Kenet, MD, Abiola Oladapo, PhD BPharm, Josh Epstein, PhD, Thompson Christin, PhD, Aaron Novack, Diane J. Nugent, MD

Blood (2017) 130 (Supplement 1): 4632.

https://doi.org/10.1182/blood.V130.Suppl_1.4632.4632

Published: 2017

Journal Articles

Economic Analysis of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Remission Induction Chemotherapy from a Hospital Management Perspective

Elif G Umit, MD, Mehmet Baysal, MD, Onur Kirkizlar, Ahmet Muzaffer Demir, MD

Blood (2017) 130 (Supplement 1): 2126.

https://doi.org/10.1182/blood.V130.Suppl_1.2126.2126

Published: 2017

Journal Articles

The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

Julia Snider, PhD, Michelle Brauer, BS, Yanni Hao, PhD, Pinar Karaca-Mandic, PhD, Mahlet Gizaw Tebeka, MS, Jie Zhang, PhD, Katharine Batt, MD MSc

Blood (2017) 130 (Supplement 1): 1330.

https://doi.org/10.1182/blood.V130.Suppl_1.1330.1330

Published: 2017

Journal Articles

Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis

Andrew Aw, MD MEng, FRCPC, Kathryn Coyle, BScPharm, MSc, Isabelle Bence-Bruckler, MD FRCPC, Christopher N. Bredeson, MD MSc, FRCPC, Doug Coyle, MA, MSc, PhD

Blood (2016) 128 (22): 1186.

https://doi.org/10.1182/blood.V128.22.1186.1186

Published: 2016

Journal Articles

Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue

Lucy Hui, Gottfried von Keudell, MD PhD, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD, Scott F Huntington, MD MPH

Blood (2016) 128 (22): 1188.

https://doi.org/10.1182/blood.V128.22.1188.1188

Published: 2016

Journal Articles

Age-Adjusted D-Dimer Cut-Off Levels to Rule-out Venous Thromboembolism in Patients with Non-High Pre-Test Probability. Clinical Performance and Cost-Effectiveness Analysis

Pierre A. Toulon, MD PhD, Neila De Pooter, MD, Marie Brionne-François, MD, Motalib Smahi, MD, Lien Abecassis, MD

Blood (2016) 128 (22): 4729.

https://doi.org/10.1182/blood.V128.22.4729.4729

Published: 2016

Journal Articles

Cost-Effectiveness Analysis of Ofatumumab As a Treatment for Relapsed Chronic Lymphocytic Leukemia in the United States

Gabriel Tremblay, DBA, MSc, BA, Anna Forsythe, PharmD, MSc, MBA, Vasudha Bal, MSc, MBA, Snigdha Santra, MS, MPH, Andrew Briggs, MSc, DPhil

Blood (2016) 128 (22): 2366.

https://doi.org/10.1182/blood.V128.22.2366.2366

Published: 2016

Journal Articles

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Nanxin Li, Chelsey Yang, Liangyi Fan, Todor Totev, Annie Guerin, MSc, Lei Chen, MDPhD

Blood (2015) 126 (23): 2090.

https://doi.org/10.1182/blood.V126.23.2090.2090

Published: 2015

Journal Articles

Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism

Nathan T. Connell, MD, M.P.H., Gregory A. Abel, MD MPH, Jean M. Connors, MD

Blood (2015) 126 (23): 746.

https://doi.org/10.1182/blood.V126.23.746.746

Published: 2015

NARROW

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Dasatinib and Nilotinib As Upfront Therapy for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in Qatar: A Cost Effectiveness Analysis (CEA)

Is It Time to Take MRD More Seriously? Relationship between MRD, Functional Cure and Life Expectancy Among Patients with Ph- B Cell Precursor ALL (BCP-ALL)

Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis

Study of Treatment-Free Remission Evaluation in Real-World Chronic Myeloid Leukemia; Cost-Effectiveness Analysis

Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective

A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim

Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Resource Utilization Using Micro-Costing Method and Cost Effectiveness Analysis of Treatment of Acute Promyelocytic Leukemia with Generic Arsenic-Trioxide

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Economic Analysis of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Remission Induction Chemotherapy from a Hospital Management Perspective

The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

Bendamustine and Rituximab Versus Conventional Chemoimmunotherapy As a Frontline Treatment for Patients with Indolent B-Cell Lymphoma: A Cost-Effectiveness Analysis

Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue

Age-Adjusted D-Dimer Cut-Off Levels to Rule-out Venous Thromboembolism in Patients with Non-High Pre-Test Probability. Clinical Performance and Cost-Effectiveness Analysis

Cost-Effectiveness Analysis of Ofatumumab As a Treatment for Relapsed Chronic Lymphocytic Leukemia in the United States

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only